Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: Business Wire
Preliminary clinical data from the Phase 1 trial expected in 2H/2026 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA.“Dosing the first patient in our clinical study of ADI-001 in treatment-refractory RA marks an important milestone in our Phase 1 program, which is now enrolling across seven autoimmune conditions,” said Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio. “In this study we are evaluating two conditioning regimens, cyclophosphamide alone and in combination with fludarabine, to explore how different conditioning regimens may impact the overall therapeutic experience. Following the recent promising safety and efficacy results of ADI-001 in lupus nephritis and systemic lupu
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Adicet Bio (NASDAQ:ACET) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Adicet Bio (NASDAQ:ACET) had its price target raised by analysts at HC Wainwright from $4.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Adicet Bio (NASDAQ:ACET) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
ACET
Earnings
- 11/5/25 - Miss
ACET
Sec Filings
- 11/17/25 - Form DEF
- 11/5/25 - Form PRE
- 11/5/25 - Form 10-Q
- ACET's page on the SEC website